Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements
Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.
INOsecurities fraudclass action lawsuit

